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Binding between the Niemann–Pick C1 protein and a
photoactivatable cholesterol analog requires a
functional sterol-sensing domain
Nobutaka Ohgami*, Dennis C. Ko†, Matthew Thomas*, Matthew P. Scott†, Catherine C. Y. Chang*,
and Ta-Yuan Chang*‡
*Department of Biochemistry, Dartmouth Medical School, Hanover, NH 03755; and †Department of Developmental Biology, Clark Center W252, 318 Campus
Drive, Stanford University School of Medicine, Stanford, CA 94305-5439
Communicated by P. Roy Vagelos, Regeneron Pharmaceuticals, Bedminster, NJ, July 20, 2004 (received for review March 10, 2004)
Niemann–Pick type C (NPC) 1 protein plays important roles in
moving cholesterol and other lipids out of late endosomes by
means of vesicular trafficking, but it is not known whether NPC1
directly interacts with cholesterol. We performed photoaffinity
labeling of intact cells expressing fluorescent protein (FP)-tagged
NPC1 by using [3H]7,7-azocholestanol ([3H]AC). After immunopre-
cipitation, 3H-labled NPC1-GFP appeared as a single band. Including
excess unlabeled sterol to the labeling reaction significantly di-
minished the labeling. Altering the NPC1 sterol-sensing domain
(SSD) with loss-of-function mutations (P692S and Y635C) severely
reduced the extent of labeling. To further demonstrate the spec-
ificity of labeling, we show that NPC2, a late endosomallysosomal
protein that binds to cholesterol with high affinity, is labeled,
whereas mutant NPC2 proteins inactive in binding cholesterol are
not. Vamp7, an abundant late endosomal membrane protein
without an SSD but with one transmembrane domain, cannot be
labeled. Binding between [3H]AC and NPC1 does not require NPC2.
Treating cells with either U-18666A, a compound that creates an
NPC-like phenotype, or with bafilomycin A1, a compound that
raises late endosomal pH, has no effect on labeling of NPC1-YFP,
suggesting that both drugs affect processes other than NPC1
binding to cholesterol. We also developed a procedure to label the
NPC1-YFP by [3H]AC in vitro and showed that cholesterol is more
effective in protection against labeling than its analogs epi-
cholesterol or 5--cholestan. Overall, the results demonstrate that
there is direct binding between NPC1 and azocholestanol; the
binding does not require NPC2 but requires a functional SSD within
NPC1.
N iemann–Pick type C (NPC) disease is a fatal neurovisceraldisorder characterized by clinically progressive hepato-
splenomegaly and central nervous system neurodegeneration
(reviewed in ref. 1). The disease involves the accumulation of
unesterified cholesterol, sphingomyelin, glycolipids, and other
lipids within the endosomallysosomal system, in cells of various
tissues (1), and in neurons (2–4). Currently there is no cure for
the disease. The disease can be caused by mutations in either of
two genetic loci, NPC1 and NPC2. Mutations in NPC1 account
for 95% of all of the NPC disease cases, whereas mutations at
NPC2 account for the remaining 5% (1).
NPC1 has been extensively studied at the cellular and molec-
ular levels. Chinese hamster ovary (CHO) cells with NPC1
mutations have been isolated, the CT60 and CT43 mutants from
25RA cells (5, 6) and other mutants from WT cells (7–9). The
human NPC1 gene encodes a 1,278-aa (170–190 kDa) glyco-
protein, with 13 putative transmembrane domains (TMD) that
include a sterol-sensing domain (SSD) located between the third
and seventh TMDs (10). The NPC2 gene encodes a soluble
lysosomal protein (11) that can be secreted into the medium and
binds cholesterol with high affinity (12). Single mutations within
the putative cholesterol-binding pocket (13), including the F66A,
V96F, and the Y100A mutants, disrupt the ability of the NPC2
to bind cholesterol in vitro (12).
SSDs consist of 180 aa organized in five consecutive mem-
brane-spanning domains. NPC1 proteins with single mutations
in the SSD, including the Y635C and the P692S mutants, are
unable to rescue the cholesterol-trafficking defect present in
CT60 cells (14, 15). The SSD is present in other membrane
proteins including hydroxymethylglutaryl (HMG)-CoA reduc-
tase (16, 17), sterol regulatory element-binding protein cleavage-
activating protein (SCAP) (18), PATCHED (19), and NPC1L1
(20). Thus, unraveling the mysteries of NPC1 will lead not only
to greater knowledge of a devastating human disease, but also to
an increased understanding of a family of proteins involved in
diverse biological functions, including dietary uptake of choles-
terol, mediation of cellular cholesterol homeostasis, and cell–cell
signaling (21, 22).
The native NPC1 protein resides mainly in late endosomes and
the related tubulovesicles (15, 23); it may interact transiently
with lysosomes and the trans-Golgi network (24, 25). In mutant
NPC1 cells, transport of cholesterol to the endosomelysosome
from low-density lipoprotein (LDL) (26, 27) or from endogenous
biosynthesis (2, 28–30) is partially defective. It has been pro-
posed that NPC1 may be involved in mediating the transport of
multiple cargo, including cholesterol, fatty acids, andor glyco-
sphingolipids, in late endosomeslysosomes (25, 31, 32). When
expressed in Escherichia coli, the NPC1 protein exhibits lipid
permease activity and transports fatty acids but not cholesterol
(33). However, there is currently no evidence for NPC1 inter-
acting directly with cholesterol or with other lipids. Photoaffinity
labeling has been widely used to demonstrate direct binding
between a macromolecule and a specific ligand (reviewed in ref.
34). We and other investigators have previously reported the
syntheses and use of two similar 3H-labeled photolabile choles-
terol analogs, [3H]6,6-azocholestanol (35) and [3H]7,7-azo-
cholestanol ([3H]AC; ref. 36; Fig. 1A shows cholesterol and AC).
When fed to intact CHO cells, [3H]AC is metabolized in manners
very similar to [3H]cholesterol (36). After photolysis, [3H]AC
cross-linked to a variety of proteins; one of them was caveolin-1,
a protein known to bind cholesterol with high affinity (36).
It is important to determine whether NPC1 binds sterols. To
test the possibility that NPC1 may directly bind [3H]AC, we
expressed fluorescent protein (FP)-tagged NPC1 protein in
CHO cells or in human fibroblast cells. Intact cell labeling
experiments using [3H]AC were used to assess binding to WT
and mutant forms of NPC1, with the mutants providing impor-
tant controls for specificity and information about SSD rele-
Freely available online through the PNAS open access option.
Abbreviations: AC, 7,7-azocholestanol; FP, fluorescent protein; IP, immunoprecipitation;
NPC, Niemann–Pick type C; SSD, sterol-sensing domain; CHO, Chinese hamster ovary; CD,
methyl--cyclodextrin.
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vance. Our findings show that NPC1 does bind sterols and that
this interaction requires an intact SSD.
Materials and Methods
Plasmids. pREX-NPC1-GFP and pREX-GFP were described in
ref. 27. pNPC1-ECFP, pNPC1-EYFP, and plasmids containing
various point mutations of pNPC1-FP were described in ref. 15.
In addition, another point mutation, D945N, was produced. This
mutation is found in people with severe NPC disease. pNPC2-
myc-his and plasmids containing various point mutations of
NPC2-myc-his were described in ref. 12. pVAMP7-YFP was
from R. Advani (Stanford University, Stanford, CA).
Cell Culture and Transfection. The CT43 and CT60 mutant cell lines
were isolated from mutagenized 25RA cells (5). Both mutants
contain the same gain-of-function mutation in SCAP as the
25RA cells (18). In addition, the CT mutants contain a prema-
ture translational termination mutation near the 3 end (for
CT43), or near the 5 end (for CT60) within the NPC1 coding
sequence, producing nonfunctional, truncated NPC1 proteins
(6). The CT60 cells stably expressing the NPC1-YFP protein
(CT60-NPC1-YFP cells) have been described (15). CHO cell
lines grown in 100-mm dishes were maintained in medium A
(Ham’s F-12, plus 10% FBS and 10 gml gentamycin) as
monolayers at 37°C with 5% CO2. The NPC2-deficient human
fibroblast cell line expressing the SV40 large T antigen was from
Dr. Yiannis A. Ioannou (37). Human fibroblasts were grown in
the same condition as the CHO cells except that DMEM was
used. For CT43 and 25RA cells, transfections with FuGENE 6
(Roche) were carried out. The cells were used for photolabeling
within 2 days after transfection. NPC2-deficient human fibro-
blasts were transfected with 5 g of pNPC1-EYFP and 15 l of
Lipofectamine 2000 (Invitrogen) in 8 ml of medium per dish, or
cotransfected with 5 g of pNPC1-EYFP, 5 g of pNPC2-myc-
his, and 30 l of Lipofectamine 2000 in 8 ml of medium per dish.
Transfected human fibroblasts were used within 16 h after
transfection.
Intact Cell Photolabeling. Transfected cells (3.0  106 cells unless
specified) were grown in medium A for 48 h. Cells were detached
by incubating with 10 mM EDTA in Hanks’ buffer (unless
specified otherwise) at room temperature for 5 min, then
pelleted by brief centrifugation into 1.5-ml Eppendorf tubes on
ice. After washing with Hanks’ buffer, the cell pellets were
preincubated with 74.6 l of 5 mM methyl--cyclodextrin (CD;
Sigma) for 15 min at 37°C. Next, 56.2 l of the prewarmed
[3H]ACCD and 68 l of CD with or without excess unlabeled
sterol were added to the cell pellets. The [3H]ACCD was
prepared at 5 mM CD, with sterolCD molar ratio at 1:64, and
with [3H]AC at 34.0 Ci (1 Ci  37 GBq) and 78.1 M. The
unlabeled sterolCD complexes were prepared at 50 mM CD,
with sterolCD molar ratio at 1:16. CD with or without sterol was
prepared in Hanks’ buffer. The mixtures (3.0  106 cells per 300
l final volume) were incubated for 1 h at 37°C, then ice-chilled
and subjected to photolysis for 15 min on ice by using the
photochemical reaction assembly (from Ace Glass; catalog no.
7825-34), with a 450-watt UV lamp at 366 nm. After photolysis,
cells were washed with ice-chilled PBS and pelleted by a
microcentrifuge. The pellets were lysed by using 1% Nonidet
P-40 lysis buffer [50 mM Tris100 mM NaCl1% Nonidet P-401
mM EDTA1 mM EGTAprotease inhibitors mixture (Sigma),
pH 7.4]. The lysates were subjected to immunoprecipitations
(IPs) as described (36), by using mouse monoclonal anti-GFP
antibody (10 g; Abcam1218), mouse monoclonal anti-c-myc
antibody [10 g; 9E10 (Roche)], or control mouse IgGs. The
immunoprecipitates were subjected to 5–15% gradient SDS
PAGE, followed by radioluminography (exposure time, 5 days
unless specified). In addition, a parallel set of samples was
subjected to 5–15% SDSPAGE, followed by immunoblotting
with rabbit anti-GFP antibodies (1:10,000; Abcam290) or with
rabbit anti-NPC2 antibodies (from P. Lobel, Robert Wood
Johnson Medical School, New Brunswick, NJ) as indicated.
LysoTracker Staining in Live Cells and Fluorescence Microscopy. Cells
(1.5  105 cells per well) were grown in medium A on glass
coverslips in six-well plates. After washing with PBS, the cells
were incubated in F-12 medium containing 150 nM LysoTracker
Red (Molecular Probes) for 1 h at 37°C in 5% CO2 incubator.
Afterward, the cells were washed two times with ice-chilled PBS
containing 0.1% BSA, and two more times with ice-chilled PBS.
The coverslips were quickly mounted with a drop of ProLong
Antifade media (Molecular Probes) onto the glass slides. Sam-
ples were viewed and photographed by using a Leica TCS SP
laser scanning confocal microscope. The images were processed
Fig. 1. Identification of NPC1 protein as an azocholestanol-binding protein. (A) Chemical structures of 7,7-azo-5-cholestan-3[3H]-3-ol ([3H]AC) and
cholesterol. (B and C) Untransfected CT43 cells (lane 1) or CT43 cells transiently transfected with pREX-GFP (lanes 2, 5, and 10), pREX-NPC1-GFP (lanes 3, 4, 6, 7,
and 11), pNPC1-EYFP (lanes 8 and 12), or pVAMP7-YFP (lanes 9 and 13) were photolabeled by using [3H]AC in the absence (lanes 1–6, 8, and 9) or presence (lane
7) of 60-fold excess of unlabeled cholesterol and processed for radioluminography (B) and Western blotting (C) according to procedures described in Materials
and Methods. Antibodies used for IP were as follows: mouse monoclonal anti-GFP antibody (lanes 5–13) or control mouse IgG (lane 4). Antibodies used for
Western blotting were as follows: rabbit anti-GFP antibodies (lanes 10–13). The labeled bands on the right are: (i) NPC1-GFP; (ii) VAMP7-YFP; (iii) GFP only. The
results shown are representative of two experiments.
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by using LEICA CONFOCAL SOFTWARE (Leica, Deerfield, IL) and
quantified by COOLLOCALIZER 1.1.2 (Cytolight Software, Wash-
ington, DC).
Preparation of the Membrane Fractions That Contain the NPC1-YFP
Protein. All procedures were performed at 4°C. CT60-NPC1-
YFP cells grown in medium A at 80% confluency, in fifteen
150-mm dishes, were scraped into the homogenization buffer (20
mM Hepes250 mM sucrose1 mM EDTAprotease inhibitors
mixture, pH 7.3), and homogenized by using a stainless steel
homogenizer (27). The postnuclear supernatants were collected
after centrifugation (1,000  g, 5 min) and were subjected to
centrifugation (16,000  g, 40 min) by using a Beckman model
70.1 Ti rotor. The pellets obtained were suspended in the
resuspension buffer (50 mM TrisHCl150 mM NaClprotease
inhibitors mixture, pH 7.4), by using a glass homogenizer
(Wheaton Scientific; 30 strokes), then repeatedly passed through
a 25-gauge needle (10 times). The resuspended membrane
fractions were used for the in vitro photolabeling experiments.
In Vitro Photolabeling. The freshly prepared membrane fractions
(600 g per sample) were preincubated in a total volume of 263
l per sample, containing 60.0 l of 50 mM CD or 60.0 l of
1.5625 mM unlabeled sterol50 mM CD (with sterol at 94.0
nmol), for 20 min at 30°C. CD solutions with or without sterols
were prepared in the resuspension buffer. After preincubation,
37.0 l of the prewarmed complex, consisting of 78.1 M
[3H]AC5 mM CD (with [3H]AC at 34.0 Ci and 3.0 nmol), was
added per sample. The mixtures (300 l final volume per sample)
were incubated for 1 h at 30°C, ice-chilled, and subjected to
photolysis for 15 min on ice as described earlier. After photolysis,
the membranes were pelleted by centrifugation (25,000  g, 30
min) by using a Beckman model 70.1 Ti rotor. The pellets were
solubilized by adding 300 l per sample of 2% Nonidet P-40 lysis
buffer (50 mM Tris100 mM NaCl2% Nonidet P-401 mM
EDTA1 mM EGTAprotease inhibitors mixture, pH 7.4) and
vortexed. The solubilized membrane fractions underwent cen-
trifugation (25,000  g, 30 min). The supernatants were col-
lected, and subjected to IP by using mouse monoclonal anti-GFP
antibody (10 g per sample), or control mouse IgGs (10 g per
sample). The immunoprecipitates were subjected to 4–14%
gradient SDSPAGE. To detect the labeled protein bands, a
gel-slicing method (38) was used (instead of the radioluminog-
raphy method). In brief, after electrophoresis, individual gel
lanes were manually cut into 6-mm slices. The sliced gels were
placed in glass vials and were dissolved in 0.5 ml per slice of 31%
H2O2 by incubating at 70–80°C for 5–6 h. Afterward, 5.0 ml per
vial of Ecoscint H (National Diagnosis) was added. After
incubation for 12 h at room temperature in a dark room, the
radioactivity levels were determined by scintillation counting. In
addition, a parallel set of samples after SDSPAGE was immu-
noblotted with rabbit anti-GFP antibodies.
Results
Labeling the NPC1 Protein with [3H]AC in Intact Cells. It is unknown
whether the normal molecular function of NPC1 involves a direct
interaction with cholesterol. To answer this question, we first
showed that [3H]AC delivered to intact 25RA cells can be
esterified and that the percentage of esterification is significantly
reduced in the NPC1-deficient CT43 cells (Fig. 6, which is
published as supporting information on the PNAS web site).
Thus, the NPC1 protein functionally interacts with AC in intact
cells. We next performed intact cell cross-linking experiments.
GFP-tagged mouse NPC1 protein was produced in CT43 cells by
transient transfection, followed by intact cell photoaffinity la-
beling using [3H]AC. The results show that, after IP, a single
band with the same molecular mass as NPC1-GFP (200 kDa) is
specifically photolabeled by [3H]AC (Fig. 1 B and C, lanes 6 and
11). The control experiment shows that GFP alone (28 kDa) is
not photolabeled by [3H]AC (Fig. 1 B and C, lanes 5 and 10).
In separate experiments, we performed intact cell photoaf-
finity labeling by using [3H]AC in cells transiently transfected
with the YFP-tagged late endosomal membrane protein Vamp7
(39). The result showed that Vamp7-YFP was not labeled by
[3H]AC (Fig. 1B, lane 9). The expression level of the Vamp7-
YFP is near that of NPC1-YFP (compare lanes 12 and 13 of Fig.
1C). Both NPC1 and Vamp7 are membrane proteins located
mainly in late endosomes; Vamp7 contains one predicted trans-
membrane domain near its C terminus (39). Thus, the interac-
tion between [3H]AC and NPC1 is not simply due to the
overexpression of an integral membrane protein that resides
within late-endosomal membranes.
Role of the SSD Within NPC1 in Mediating the Binding Between NPC1
Protein and [3H]AC in Intact Cells. Further evidence of the speci-
ficity of the NPC1–sterol interaction comes from analyzing
loss-of-function mutations in a specific domain within NPC1. We
performed photolabeling experiments in CT43 cells expressing
either WT NPC1 or one of three loss-of-function mutant NPC1
proteins [P692S and Y635C (15) and D945N]. Each of these
three point mutations inactivates the NPC1 protein’s ability to
mobilize cholesterol from late endosomes (ref. 15; D.C.K.,
Fig. 2. Role of the SSD within NPC1 in mediating the binding between NPC1 protein and [3H]AC. (A) Effect of NPC1 mutations within the sterol-sensing domain
on [3H]AC labeling. CT43 cells (3.0  106) or 25RA cells (6.0  106) transiently transfected with WT or various mutant pNPC1-FP as indicated were photolabeled
by using [3H]AC and processed for radioluminography (RL) and Western blotting (WB) according to procedures as described in Materials and Methods. The results
using CT43 cells are representative of four experiments. The results using 25RA cells are representative of two experiments. (B) Percentage colocalization of
NPC1-FP with LysoTracker. CT43 or 25RA cells were plated in wells with coverslips, grown in medium A, transiently transfected with various NPC1-FP constructs
as indicated, and then grown in medium A for 48 h. Afterward, cells were stained with LysoTracker red and viewed under a confocal microscope according to
procedures described in Materials and Methods. Red signal, LysoTracker; green signal, NPC1-FP. The yellow signal indicates colocalization of the red and green
signals. Values given are the percentage colocalization between LysoTracker and a given NPC1-FP as indicated. To estimate percentage colocalization for each
construct, results from six different images were averaged and quantified by using COOLLOCALIZER 1.1.2 (Cytolight). Only the results using CT43 cells were shown.
The results expressing various NPC1 constructs in 25RA cells as the host were very similar to those reported in CT43 cells.








unpublished data). For the two NPC1 proteins that contain point
mutations within the SSD [P692S and Y635C (15)], the results
show much diminished labeling (Fig. 2A). In the third mutant
(D945N), which contains a point mutation outside the SSD, the
labeling is not diminished. These results suggest that the differ-
ence in labeling between the WT and the two SSD mutant NPC1
is not simply due to the loss of function of the two SSD mutants.
To strengthen these results, in a separate experiment, we used
25RA cells instead of CT43 cells as the host for expression and
compared the labeling of the WT and the two SSD mutants. The
25RA cells contain an active, endogenous NPC1, whereas the
CT43 cells do not. We obtained the same result as in CT43 cells
(Fig. 2 A Right). These data indicate that the difference in
labeling between the WT and the two mutant SSD NPC1
proteins does not depend on whether the host cells contain a
functional NPC1. Further experiments on protein localization
were done to address the possibility that the different amounts
of cross-linking with mutant vs. WT NPC1 proteins were due to
changes in their subcellular localizations. WT NPC1 is localized
mainly in late endosomes, whereas certain mutant NPC1s are
mislocalized to the endoplasmic reticulum (ER) (15). Lyso-
Tracker is a fluorescent dye that mainly stains the highly acidic
subcellular organelles, i.e., the late endosomeslysosomes, in live
cells. We compared the degree of colocalization between various
NPC1s and LysoTracker in CT43 cells. The results show that WT
NPC1 and the P692S mutant protein significantly colocalize with
LysoTracker (Fig. 2B Upper Left and Lower Left, 55% and 51%,
respectively). The Y635C mutant colocalizes much less with
LysoTracker (Fig. 2B Upper Right, 27%). The D945N mutant
also significantly colocalizes with the LysoTracker (Fig. 2B
Lower Right, 55%). Results similar to those shown in Fig. 2 were
obtained when 25RA cells were used as the host for expression
(results not shown). Thus, the large difference in [3H]AC
labeling between the WT NPC1 and the P692S mutant NPC1
(Fig. 2 A) is unlikely to be accounted for by the small difference
in their intracellular localizations (Fig. 2B). We conclude that
mutations within the SSD specifically interrupt the binding
between [3H]AC and NPC1 in intact cells.
Role of NPC2 in Mediating the Binding Between NPC1 Protein and
[3H]AC in Intact Cells. The other protein that is mutated in NPC
disease, NPC2, is a soluble protein, mainly located within the
lumen of late endosomeslysosomes, that binds cholesterol with
high affinity in vitro (12). We now ask two questions: (i) Can
NPC2 also be labeled with [3H]AC in intact cells? (ii) Does the
binding of [3H]AC to NPC1 require the presence of NPC2?
Here, we show that NPC2 protein tagged with myc-his at the C
terminus can be labeled by [3H]AC by using the same photola-
beling procedure (Fig. 3, left lanes). For any of the three
different point mutations of NPC2 that disrupts the cholesterol
binding activity of NPC2 in vitro [F66A, V96F, Y100A (12)], its
labeling by [3H]AC is much diminished (Fig. 3). These results
further support the interpretation that the labeling seen by using
our procedure is based on AC behaving as an analog of
cholesterol.
It has been proposed that NPC2 may be necessary to mediate
the interaction between NPC1 and cholesterol (for example, ref.
40). To address this question, we expressed NPC1 alone or with
NPC2 in a mutant human fibroblast cell line known to lack NPC2
(37) and then performed intact cell labeling with [3H]AC. The
results show that the association between [3H]AC and NPC1 in
cells with or without added NPC2 is approximately equal (Fig.
4). Thus, binding between AC and NPC1 does not require NPC2.
Labeling of NPC1-YFP by [3H]AC in Vitro and Protection Against
Labeling by Various Unlabeled Steroids Added in Excess. To further
test the specificity of labeling between NPC1 and [3H]AC, we
prepared membrane fractions from cells that stably express the
NPC1-YFP and performed photolabeling by [3H]AC in vitro.
After labeling, the membranes were solubilized by detergent; the
NPC1-YFP was then isolated by IP followed by SDSPAGE. To
evaluate the labeling more precisely, we quantitated the labeling
by gel slicing. The results showed (Fig. 5A) that NPC1-YFP can
be labeled by [3H]AC in vitro and that excess CD present in the
labeling mixture does not significantly affect the extent of
labeling. By using this procedure, we next tested the abilities of
various unlabeled steroids, added in excess as a CD complex, to
protect against labeling. The results showed that cholesterol is
more effective in protection than its analog epi-cholesterol (a
sterol with the OH-moiety at  orientation), or 5- cholestan (a
steroid without the OH-moiety at C-3). Thus, the NPC1 protein
may contain a specific binding site(s) that recognizes the 3- OH
moiety of the steroid ring. We also noted that cholesterol present
in 30-fold excess only partially inhibited the [3H]AC labeling (by
30%; results seen in two experiments). Thus, NPC1 may bind
cholesterol with low affinity.
Effects of Various Agents on Labeling Between NPC1 Protein and
[3H]AC in Intact Cells. U-18666A is a hydrophobic compound that
produces an NPC phenotype in treated cells (41). One mode of
Fig. 3. Intact cell photolabeling of NPC2-myc-his with [3H]AC. CT43 cells
transiently transfected with WT or with various mutant NPC2-myc-his con-
structs as indicated were photolabeled by using [3H]AC according to proce-
dures described in Materials and Methods. The IPs were with mouse mono-
clonal anti-c-myc antibody or with control mouse IgG as indicated. RL,
radioluminography; WB, Western blotting. The Western blotting was with
rabbit polyclonal anti-NPC2 antibodies. Results are representative of two
experiments. Fig. 4. Intact cell photolabeling of NPC1 in the presence or absence of NPC2.
NPC2-deficient human fibroblast (NPC2 def. hf) cells (8.0  106 cells) tran-
siently transfected with pNPC1-YFP only (lane 1) or with pNPC1-YFP and
pNPC2-myc-his (lane 2) were photolabeled by using [3H]AC. DMEM without
phenol red, instead of Hanks’ buffer, was used as the incubation buffer. The
samples were processed for radioluminography (RL; exposure time, 7 days)
and Western blotting (WB; with rabbit anti-GFP antibodies or with rabbit
polyclonal anti-NPC2 antibodies as indicated). Lanes: 1, without pNPC2-myc-
his; 2, with pNPC2-myc-his. Results are representative of two experiments.
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its action could be to compete with the association of cholesterol
with NPC1. Adding U-18666A to CT60-NPC1-YFP cells for a
short period (15 min) or for a long period (36 h) before
cross-linking causes no significant alteration in the degree of
labeling in intact cells (Fig. 7A, which is published as supporting
information on the PNAS web site). Thus, the binding between
AC and NPC1 is not altered by U-18666A. NPC1 seems to be a
distant member of the RND permease family that functions
through a proton-antiport mechanism (33). Thus, disrupting the
proton gradient might interfere with labeling. To test this
possibility, we found that treating cells with bafilomycin A1, a
compound that interferes with vacuolar H-ATPase and raises
endosomallysosomal pH (42), caused no significant alteration
in degree of labeling intact cells (Fig. 7B). Parallel control
experiments showed that cells treated with bafilomycin A1 lost
their ability to concentrate the fluorescent dye LysoTracker
(result not shown). Thus, the binding between [3H]AC and NPC1
does not require an acidic pH environment.
Discussion
The results of our experiments show that the NPC1 protein can
be labeled by a photoactivatable cholesterol analog in intact
cells. The labeling, which implies direct binding between [3H]AC
and NPC1, does not require NPC2. Binding does not need an
acidic environment and is not restricted to cells that exhibit a
NPC1 phenotype. Under our labeling conditions, AC also effi-
ciently labels NPC2, a protein already known to bind cholesterol
with high affinity in vitro. AC hardly labels various mutant
NPC2s that are known to be inactive in binding cholesterol, nor
does AC label Vamp7, an integral membrane protein that is
abundantly expressed in the same compartments (late endo-
someslysosomes) as NPC1. We also showed that the NPC1-YFP
present in membranes could be labeled by [3H]AC in vitro;
cholesterol added in excess is more effective in protection against
labeling than its analog epi-cholesterol or 5--cholestan. Cho-
lesterol provided only partial protection against labeling in vitro.
Taken together, our results strongly suggest that NPC1 is a
low-affinity cholesterol-binding protein.
Two ideas about mechanism arise from the binding of sterol
to NPC1. (i) NPC1 binds to cholesterol as its substrate and
transports it at the late endosomal membrane; this possibility
would be consistent with the current finding that NPC1 binds to
cholesterol with low affinity. (ii) NPC1 participates in transport-
ing various substancescomplexes at the endosomal membrane;
its activity is modulated by cholesterol bound as an allosteric
regulator. These two possibilities are not mutually exclusive, and
further investigations are required for resolution. If NPC1
transports cholesterol, it apparently does not use NPC2 bound to
cholesterol as a donor for binding cholesterol. Additional results
presented here indicate that a functional SSD is required for
NPC1 to bind [3H]AC. To our knowledge, the current report
provides the first evidence that a protein containing an SSD
directly binds to a cholesterol analog. Several proteins, among
others, contain SSDs: (i) HMG-CoA reductase, a rate-
controlling enzyme in cholesterol biosynthesis (43); (ii) SCAP, a
protein that forms a complex with the SRE binding proteins
(SREBPs) and translocates from the endoplasmic reticulum
(ER) to the Golgi in response to cholesterol deprivation in the
ER (44); (iii) PATCHED, a tumor suppressor involved in the
signal transduction cascade mediated by the cholesterol-
modified morphogen Hedgehog (19); and (iv) NPC1L1, a pro-
tein recently reported to be involved in intestinal cholesterol
absorption (20). These proteins all participate in various cho-
lesterol-dependent regulatory events in some manner, and the
SSDs present in these proteins play important roles in mediating
the functions of these proteins (reviewed in ref. 22). On the other
hand, whether binding occurs between sterol(s) and any of these
SSD proteins and, if so, whether an SSD is required have not
Fig. 5. Photolabelings of NPC1-YFP in vitro and protections against
labeling by various agents. (A) The membrane fractions from CT60-NPC1-
YFP cells were preincubated in buffer, in the presence [center and right
lanes in the Western blotting (WB; Left) panel; filled and open circles in the
gel slicing (Right) panel] or absence (left lane in the WB panel; open
triangles in the gel slicing panel) of 50 mM CD for 20 min at 30°C, then
photolabeled with 5 mM CD complexed with [3H]AC, according to proce-
dures described in Materials and Methods. The labeled samples were
subjected to IP with mouse monoclonal anti-GFP antibody (left and center
lanes in the WB panel; open triangles and filled circles in the gel slicing
panel), or with control mouse IgGs (left lane in the WB panel; open circles
in the gel slicing panel). Western blotting with anti-GFP antibodies or gel
slicing was performed according to procedures described in Materials and
Methods. Results shown are representative of two experiments. (B) The
membrane fractions from CT60-NPC1-YFP cells were preincubated for 20
min at 30°C in buffer containing 50 mM CD only (lane 1; CD only), or 50 mM
CD complexed with an unlabeled steroid as indicated (lanes 2– 4). Lanes: 2,
cholesterol (5-cholesten-3-ol); 3, epicholesterol (5-cholesten-3-ol); 4,
5-cholestan. Afterward, 5 mM CD complexed with [3H]-AC was added, and
the samples were photolabeled, according to procedures described in
Materials and Methods. Raw radioactivity was the sum of the radioactivity
of gel slices 3–5. Results from WB were quantified by using NIH IMAGE 1.63; the
values obtained are shown at the bottom of each lane. The assays were
done in duplicate; the results of the duplicates are shown. (C) Normalized
radioactivity. The values were obtained by dividing the raw radioactivities
by the mean pixel intensities shown in B. The results shown were the
averages of duplicate assays. Results shown in B and C are representative of two
experiments.








been tested. We have attempted to label two of these SSD
proteins, the HMG-CoA reductase and PATCHED, each tagged
with GFP, with [3H]AC by using the intact cell-labeling proce-
dure described here. We were not able to detect significant
labeling between [3H]AC and either one of these two proteins
(data not shown), but the expression levels of HMG-CoA
reductase-GFP and PATCHED-GFP in CHO cells were much
lower than those of NPC1-GFP (5%). Thus, a much better
expression system will probably be needed to attempt photola-
beling of AC with SSD proteins that are in low abundance in
intact cells.
In NPC1NPC1 homozygous mutant cells, abnormal accumu-
lation of various sphingolipids (i.e., sphingomyelin, glucosylce-
ramide, galactosylceramide, and the gangliosides GM2 and
GM3) is observed in addition to alterations in cholesterol
trafficking (reviewed in refs. 45–48). NPC1 protein may also
bind other lipids in addition to binding cholesterol. In the future,
these possibilities can be addressed by performing cross-linking
studies using different photoaffinity probes in intact cells,
andor by using various biochemical procedures that allow
investigators to study binding of NPC1 and various ligands in
liposomes, or in detergent-solubilized conditions in vitro.
Note Added in Proof. Radhakrishnan et al. (49) very recently reported
that SCAP, another polytopic membrane protein that contains the SSD,
binds cholesterol with high affinity in vitro.
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